Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia

Schizophrenia Research

Volumn 159, Issue 1, 2014, Pages 124-129

  Volk, David W ^a   Eggan, Stephen M ^a   Horti, Andrew G ^b   Wong, Dean F ^b   Lewis, David A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabinoid; Cannabis; CB1R; Marijuana; PET; Prefrontal cortex; Radioligand; Rimonabant; Schizophrenia

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; HYDROGEN 4 CYANO 1 (2,4 DICHLOROPHENYL) 5 (4 METHOXYPHENYL) N (PIPERIDIN 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE H 3; MESSENGER RNA; RADIOLIGAND; RIMONABANT; UNCLASSIFIED DRUG; 4-CYANO-1-(2,4-DICHLOROPHENYL)-5-(4-METHOXYPHENYL)-N-(PIPERIDIN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE; CNR1 PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; PROTEIN BINDING; PYRAZOLE DERIVATIVE; TRITIUM;

ADULT; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BINDING AFFINITY; CANNABIS USE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GRAY MATTER; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MALE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PROTEIN BINDING; PROTEIN IMMUNOREACTIVITY; QUANTITATIVE STUDY; RADIOIMMUNOASSAY; SCHIZOPHRENIA; ANALYSIS OF VARIANCE; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; ANALYSIS OF VARIANCE; AUTORADIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PROTEIN BINDING; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; SCHIZOPHRENIA; TRITIUM;

EID: 84908048904     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.07.017     Document Type: Article

References (30)

1. American Psychiatric Association DSM-IV. Diagnostic and Statistical Manual of Mental Disorders 1994, 4. American Psychiatric Association, Washington, D.C. Fourth Edition.
2. Casadio P., Fernandes C., Murray R.M., Di Forti M. Cannabis use in young people: the risk for schizophrenia. Neurosci. Biobehav. Rev. 2011, 35:1779-1787.
3. Compton M.T., Kelley M.E., Ramsay C.E., Pringle M., Goulding S.M., Esterberg M.L., Stewart T., Walker E.F. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am. J. Psychiatry 2009, 166:1251-1257.
4. Dalton V.S., Long L.E., Weickert C.S., Zavitsanou K. Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology 2011, 36:1620-1630.
5. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103:9-15.
6. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 2005, 57:594-608.
7. Eggan S.M., Lewis D.A. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb. Cortex 2007, 17:175-191.
8. Eggan S.M., Hashimoto T., Lewis D.A. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry 2008, 65:772-784.
9. Eggan S.M., Melchitzky D.S., Sesack S.R., Fish K.N., Lewis D.A. Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience 2010, 169:1651-1661.
10. Eggan S.M., Stoyak S.R., Verrico C.D., Lewis D.A. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology 2010, 35:2060-2071.
11. 11C]JHU75575) as potential radioligands for PET imaging of cerebral cannabinoid receptor. J. Label. Compd. Radiopharm. 2006, 49:1021-1036.
12. Foti D.J., Kotov R., Guey L.T., Bromet E.J. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am. J. Psychiatry 2010, 167:987-993.
13. Galvez-Buccollini J.A., Proal A.C., Tomaselli V., Trachtenberg M., Coconcea C., Chun J., Manschreck T., Fleming J., DeLisi L.E. Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis. Schizophr. Res. 2012, 139:157-160.
14. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J. Nucl. Med. 2006, 47:1689-1696.
15. Jenko K.J., Hirvonen J., Henter I.D., Anderson K.B., Zoghbi S.S., Hyde T.M., Deep-Soboslay A., Innis R.B., Kleinman J.E. Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophr. Res. 2012, 141:185-188.
16. Koethe D., Llenos I.C., Dulay J.R., Hoyer C., Torrey E.F., Leweke F.M., Weis S. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J. Neural Transm. 2007, 114:1055-1063.
17. Marrs W.R., Blankman J.L., Horne E.A., Thomazeau A., Lin Y.H., Coy J., Bodor A.L., Muccioli G.G., Hu S.S., Woodruff G., Fung S., Lafourcade M., Alexander J.P., Long J.Z., Li W., Xu C., Moller T., Mackie K., Manzoni O.J., Cravatt B.F., Stella N. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat. Neurosci. 2010, 13:951-957.
18. Newell K.A., Deng C., Huang X.F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res. 2006, 172:556-560.
19. Pierri J.N., Chaudry A.S., Woo T.-U., Lewis D.A. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am. J. Psychiatry 1999, 156:1709-1719.
20. Price M.R., Baillie G.L., Thomas A., Stevenson L.A., Easson M., Goodwin R., McLean A., McIntosh L., Goodwin G., Walker G., Westwood P., Marrs J., Thomson F., Cowley P., Christopoulos A., Pertwee R.G., Ross R.A. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 2005, 68:1484-1495.
21. Rajkowska G., Goldman-Rakic P.S. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Cereb. Cortex 1995, 5:307-322.
22. Uriguen L., Garcia-Fuster M.J., Callado L.F., Morentin B., La Harpe R., Casado V., Lluis C., Franco R., Garcia-Sevilla J.A., Meana J.J. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl) 2009, 206:313-324.
23. Volk D.W., Austin M.C., Pierri J.N., Sampson A.R., Lewis D.A. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 2000, 57:237-245.
24. Volk D.W., Eggan S.M., Lewis D.A. Alterations in metabotropic glutamate receptor 1alpha and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am. J. Psychiatry 2010, 167:1489-1498.
25. Volk D.W., Radchenkova P.V., Walker E.M., Sengupta E.J., Lewis D.A. Cortical opioid markers in schizophrenia and across postnatal development. Cereb. Cortex 2011, 22:1215-1223.
26. Volk D.W., Matsubara T., Li S., Sengupta E.J., Georgiev D., Minabe Y., Sampson A., Hashimoto T., Lewis D.A. Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia. Am. J. Psychiatry 2012, 169:1082-1091.
27. Volk D.W., Siegel B.I., Verrico C.D., Lewis D.A. Endocannabinoid metabolism in the prefrontal cortex in schizophrenia. Schizophr. Res. 2013, 147:53-57.
28. 11C]OMAR. NeuroImage 2010, 52:1505-1513.
29. Wong D.F., Kuwabara H., Horti A.G., Brasic J.R., Raymont V., Nandi A., Rahmim A., Gean E., Dannals R.F., Cascella N. Cannabinoid Receptor Subtype 1 (CB1) Distribution Correlates With Neuropsychiatric Ratings 2012, Society of Biological Psychiatry Abstract.
30. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:355-360.